Human DNA Ligases: A Comprehensive New Look for Cancer Therapy

Medicinal Research Reviews

Volumn 34, Issue 3, 2014, Pages 567-595

  Singh, Deependra Kumar ^a   Krishna, Shagun ^a   Chandra, Sharat ^a   Shameem, Mohammad ^a   Deshmukh, Amit Laxmikant ^a   Banerjee, Dibyendu ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Cancer drug; Cancer target; DNA ligase; Inhibitor; Ligase; Ligase inhibitor

Indexed keywords

LIGASE INHIBITOR; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

ARTICLE; BACTERIUM; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL DEATH; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; DRUG TREATMENT FAILURE; ENZYME INHIBITION; EUKARYOTE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN;

CANCER DRUG; CANCER TARGET; DNA LIGASE; INHIBITOR; LIGASE; LIGASE INHIBITOR;

AMINO ACID SEQUENCE; DNA LIGASES; ENZYME INHIBITORS; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84896905278     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21298     Document Type: Article

References (70)

1. Lehman IR. DNA ligase: Structure, mechanism, and function. Science 1974;186(4166):790-797.
2. Pascal JM. DNA and RNA ligases: Structural variations and shared mechanisms. Curr Opin Struct Biol 2008;18(1):96-105.
3. Wilkinson A, Day J, Bowater R. Bacterial DNA ligases. Mol Microbiol 2001;40(6):1241-1248.
4. Moser J, Kool H, Giakzidis I, Caldecott K, Mullenders LH, Fousteri MI. Sealing of chromosomal DNA nicks during nucleotide excision repair requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific manner. Mol Cell 2007;27(2):311-323.
5. Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair in mammalian cells: Base excision repair: The long and short of it. Cell Mol Life Sci 2009;66(6):981-993.
6. Dianov GL. Base excision repair targets for cancer therapy. Am J Cancer Res 2011;1(7):845-851.
7. Wilson TE, Grawunder U, Lieber MR. Yeast DNA ligase IV mediates non-homologous DNA end joining. Nature 1997;388(6641):495-498.
8. Liang L, Deng L, Nguyen SC, Zhao X, Maulion CD, Shao C, Tischfield JA. Human DNA ligases I and III, but not ligase IV, are required for microhomology-mediated end joining of DNA double-strand breaks. Nucleic Acids Res 2008;36(10):3297-3310.
9. Ellenberger T, Tomkinson AE. Eukaryotic DNA ligases: Structural and functional insights. Annu Rev Biochem 2008;77:313-338.
10. Chrzanowska KH, Gregorek H, Dembowska-Baginska B, Kalina MA, Digweed M. Nijmegen breakage syndrome (NBS). Orphanet J Rare Dis 2012;7:13.
11. Noguiez P, Barnes DE, Mohrenweiser HW, Lindahl T. Structure of the human DNA ligase I gene. Nucleic Acids Res 1992;20(15):3845-3850.
12. Teraoka H, Sawai M, Yamamoto K, Tsukada K. DNA ligase I mRNA and enzyme levels in human hematopoietic cells under dimethyl sulfoxide-induced growth-arrest and differentiation. Biochem Int 1992;26(5):963-971.
13. Jessberger R, Schar P, Robins P, Ferrari E, Riwar B, Hubscher U. Regulation of DNA metabolic enzymes upon induction of preB cell development and V(D)J recombination: Up-regulation of DNA polymerase delta. Nucleic Acids Res 1997;25(2):289-296.
14. Sun D, Urrabaz R, Nguyen M, Marty J, Stringer S, Cruz E, Medina-Gundrum L, Weitman S. Elevated expression of DNA ligase I in human cancers. Clin Cancer Res 2001;7(12):4143-4148.
15. Barnes DE, Tomkinson AE, Lehmann AR, Webster AD, Lindahl T. Mutations in the DNA ligase I gene of an individual with immunodeficiencies and cellular hypersensitivity to DNA-damaging agents. Cell 1992;69(3):495-503.
16. Webster AD, Barnes DE, Arlett CF, Lehmann AR, Lindahl T. Growth retardation and immunodeficiency in a patient with mutations in the DNA ligase I gene. Lancet 1992;339(8808):1508-1509.
17. Prigent C, Satoh MS, Daly G, Barnes DE, Lindahl T. Aberrant DNA repair and DNA replication due to an inherited enzymatic defect in human DNA ligase I. Mol Cell Biol 1994;14(1):310-317.
18. Hsieh CL, Arlett CF, Lieber MR. V(D)J recombination in ataxia telangiectasia, Bloom's syndrome, and a DNA ligase I-associated immunodeficiency disorder. J Biol Chem 1993;268(27):20105-20109.
19. Aboussekhra A, Biggerstaff M, Shivji MK, Vilpo JA, Moncollin V, Podust VN, Protic M, Hubscher U, Egly JM, Wood RD. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell 1995;80(6):859-868.
20. Lakshmipathy U, Campbell C. The human DNA ligase III gene encodes nuclear and mitochondrial proteins. Mol Cell Biol 1999;19(5):3869-3876.
21. Cappelli E, Taylor R, Cevasco M, Abbondandolo A, Caldecott K, Frosina G. Involvement of XRCC1 and DNA ligase III gene products in DNA base excision repair. J Biol Chem 1997;272(38):23970-23975.
22. Grawunder U, Zimmer D, Fugmann S, Schwarz K, Lieber MR. DNA ligase IV is essential for V(D)J recombination and DNA double-strand break repair in human precursor lymphocytes. Mol Cell 1998;2(4):477-484.
23. Smith J, Riballo E, Kysela B, Baldeyron C, Manolis K, Masson C, Lieber MR, Papadopoulo D, Jeggo P. Impact of DNA ligase IV on the fidelity of end joining in human cells. Nucleic Acids Res 2003;31(8):2157-2167.
24. Caldecott KW, Tucker JD, Stanker LH, Thompson LH. Characterization of the XRCC1-DNA ligase III complex in vitro and its absence from mutant hamster cells. Nucleic Acids Res 1995;23(23):4836-4843.
25. Della-Maria J, Zhou Y, Tsai MS, Kuhnlein J, Carney JP, Paull TT, Tomkinson AE. Human Mre11/human Rad50/Nbs1 and DNA ligase IIIalpha/XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway. J Biol Chem 2011;286(39):33845-33853.
26. Arakawa H, Bednar T, Wang M, Paul K, Mladenov E, Bencsik-Theilen AA, Iliakis G. Functional redundancy between DNA ligases I and III in DNA replication in vertebrate cells. Nucleic Acids Res 2012;40(6):2599-2610.
27. Le Chalony C, Hoffschir F, Gauthier LR, Gross J, Biard DS, Boussin FD, Pennaneach V. Partial complementation of a DNA ligase I deficiency by DNA ligase III and its impact on cell survival and telomere stability in mammalian cells. Cell Mol Life Sci 2012;69(17):2933-2949.
28. Tomkinson AE, Tappe NJ, Friedberg EC. DNA ligase I from Saccharomyces cerevisiae: Physical and biochemical characterization of the CDC9 gene product. Biochemistry 1992;31(47):11762-11771.
29. McVey M, Lee SE. MMEJ repair of double-strand breaks (director's cut): Deleted sequences and alternative endings. Trends Genet 2008;24(11):529-538.
30. Timson DJ, Singleton MR, Wigley DB. DNA ligases in the repair and replication of DNA. Mutat Res 2000;460(3-4):301-318.
31. Featherstone C, Jackson SP. DNA double-strand break repair. Curr Biol 1999;9(20):R759-761.
32. Wei YF, Robins P, Carter K, Caldecott K, Pappin DJ, Yu GL, Wang RP, Shell BK, Nash RA, Schar P, Barnes DE, Haseltine WA, Lindahl T. Molecular cloning and expression of human cDNAs encoding a novel DNA ligase IV and DNA ligase III, an enzyme active in DNA repair and recombination. Mol Cell Biol 1995;15(6):3206-3216.
33. Robins P, Lindahl T. DNA ligase IV from HeLa cell nuclei. J Biol Chem 1996;271(39):24257-24261.
34. Frank KM, Sekiguchi JM, Seidl KJ, Swat W, Rathbun GA, Cheng HL, Davidson L, Kangaloo L, Alt FW. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. Nature 1998;396(6707):173-177.
35. Grawunder U, Wilm M, Wu X, Kulesza P, Wilson TE, Mann M, Lieber MR. Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells. Nature 1997;388(6641):492-495.
36. Barnes DE, Stamp G, Rosewell I, Denzel A, Lindahl T. Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice. Curr Biol 1998;8(25):1395-1398.
37. Tobin LA, Robert C, Nagaria P, Chumsri S, Twaddell W, Ioffe OB, Greco GE, Brodie AH, Tomkinson AE, Rassool FV. Targeting abnormal DNA repair in therapy-resistant breast cancers. Mol Cancer Res 2012;10(1):96-107.
38. Pascal JM, O'Brien PJ, Tomkinson AE, Ellenberger T. Human DNA ligase I completely encircles and partially unwinds nicked DNA. Nature 2004;432(7016):473-478.
39. Zhong S, Chen X, Zhu X, Dziegielewska B, Bachman KE, Ellenberger T, Ballin JD, Wilson GM, Tomkinson AE, MacKerell AD, Jr. Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J Med Chem 2008;51(15):4553-4562.
40. Tomkinson AE, Totty NF, Ginsburg M, Lindahl T. Location of the active site for enzyme-adenylate formation in DNA ligases. Proc Natl Acad Sci USA 1991;88(2):400-404.
41. Yang SW, Becker FF, Chan JY. Inhibition of human DNA ligase I activity by zinc and cadmium and the fidelity of ligation. Environ Mol Mutagen 1996;28(1):19-25.
42. Chen X, Zhong S, Zhu X, Dziegielewska B, Ellenberger T, Wilson GM, MacKerell AD, Jr., Tomkinson AE. Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res 2008;68(9):3169-3177.
43. Yang SW, Huang P, Plunkett W, Becker FF, Chan JY. Dual mode of inhibition of purified DNA ligase I from human cells by 9-beta-D-arabinofuranosyl-2-fluoroadenine triphosphate. J Biol Chem 1992;267(4):2345-2349.
44. De Ioannes P, Malu S, Cortes P, Aggarwal AK. Structural basis of DNA ligase IV-Artemis interaction in nonhomologous end-joining. Cell Rep 2012;2(6):1505-1512.
45. Srivastava M, Nambiar M, Sharma S, Karki SS, Goldsmith G, Hegde M, Kumar S, Pandey M, Singh RK, Ray P, Natarajan R, Kelkar M, De A, Choudhary B, Raghavan SC. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 2012;151(7):1474-1487.
46. Ochi T, Wu Q, Chirgadze DY, Grossmann JG, Bolanos-Garcia VM, Blundell TL. Structural insights into the role of domain flexibility in human DNA ligase IV. Structure 2012;20(7):1212-1222.
47. Aubel-Sadron G, Londos-Gagliardi D. Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie 1984;66(5):333-352.
48. Ciarrocchi G, Lestingi M, Fontana M, Spadari S, Montecucco A. Correlation between anthracycline structure and human DNA ligase inhibition. Biochem J 1991;279(Pt 1):141-146.
49. Montecucco A, Fontana M, Focher F, Lestingi M, Spadari S, Ciarrocchi G. Specific inhibition of human DNA ligase adenylation by a distamycin derivative possessing antitumor activity. Nucleic Acids Res 1991;19(5):1067-1072.
50. Nordberg GF. Historical perspectives on cadmium toxicology. Toxicol Appl Pharmacol 2009;238(3):192-200.
51. Givens JF, Manly KF. Inhibition of RNA-directed DNA polymerase by aurintricarboxylic acid. Nucleic Acids Res 1976;3(2):405-418.
52. Sun D, Urrabaz R. Development of non-electrophoretic assay method for DNA ligases and its application to screening of chemical inhibitors of DNA ligase I. J Biochem Biophys Methods 2004;59(1):49-59.
53. Arcamone F, Penco S, Orezzi P, Nicolella V, Pirelli A. Structure and synthesis of distamycin A. Nature 1964;203:1064-1065.
54. Zimmer C, Wahnert U. Nonintercalating DNA-binding ligands: Specificity of the interaction and their use as tools in biophysical, biochemical and biological investigations of the genetic material. Prog Biophys Mol Biol 1986;47(1):31-112.
55. Barbieri B GF, Pozzoni G, Lazzari E, Arcamone F, Mongelli N. In vivo antitumor activity of FCE24517, a novel distamycin A derivative with specificity for ATP dependent DNA ligase. Proc Am Assoc Cancer Res 1988;29:330.
56. Dwivedi N, Dube D, Pandey J, Singh B, Kukshal V, Ramachandran R, Tripathi RP. NAD(+)-dependent DNA ligase: A novel target waiting for the right inhibitor. Med Res Rev 2008;28(4):545-568.
57. Ciarrocchi G, MacPhee DG, Deady LW, Tilley L. Specific inhibition of the eubacterial DNA ligase by arylamino compounds. Antimicrob Agents Chemother 1999;43(11):2766-2772.
58. David JC, Bassez T, Bonhommet M, Rusquet R. Inhibition of DNA ligase from human thymocytes and normal or leukemic lymphocytes by antileukemic drugs. Cancer Res 1985;45(5):2177-2183.
59. Tan GT, Lee S, Lee IS, Chen J, Leitner P, Besterman JM, Kinghorn AD, Pezzuto JM. Natural-product inhibitors of human DNA ligase I. Biochem J 1996;314(Pt 3):993-1000.
60. Messmer WM, Tin-Wa M, Fong HH, Bevelle C, Farnsworth NR, Abraham DJ, Trojanek J. Fagaronine, a new tumor inhibitor isolated from Fagara zanthoxyloides Lam. (Rutaceae). J Pharm Sci 1972;61(11):1858-1859.
61. Montecucco A, Biamonti G, Savini E, Focher F, Spadari S, Ciarrocchi G. DNA ligase I gene expression during differentiation and cell proliferation. Nucleic Acids Res 1992;20(23):6209-6214.
62. Guha M. PARP inhibitors stumble in breast cancer. Nat Biotechnol 2011;29(5):373-374.
63. Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond. Mol Aspects Med 2013. In press. doi: 10.1016/j.mam.2013.01.006.
64. Tobin LA, Robert C, Rapoport AP, Gojo I, Baer MR, Tomkinson AE, Rassool FV. Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias. Oncogene 2013;32(14):1784-1793.
65. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007;6(3):231-248.
66. Montecucco A, Rossi R, Levin DS, Gary R, Park MS, Motycka TA, Ciarrocchi G, Villa A, Biamonti G, Tomkinson AE. DNA ligase I is recruited to sites of DNA replication by an interaction with proliferating cell nuclear antigen: Identification of a common targeting mechanism for the assembly of replication factories. EMBO J 1998;17(13):3786-3795.
67. Punchihewa C, Inoue A, Hishiki A, Fujikawa Y, Connelly M, Evison B, Shao Y, Heath R, Kuraoka I, Rodrigues P, Hashimoto H, Kawanishi M, Sato M, Yagi T, Fujii N. Identification of small molecule proliferating cell nuclear antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication. J Biol Chem 2012;287(17):14289-14300.
68. Vijayakumar S, Dziegielewska B, Levin DS, Song W, Yin J, Yang A, Matsumoto Y, Bermudez VP, Hurwitz J, Tomkinson AE. Phosphorylation of human DNA ligase I regulates its interaction with replication factor C and its participation in DNA replication and DNA repair. Mol Cell Biol 2009;29(8):2042-2052.
69. Ferrari G, Rossi R, Arosio D, Vindigni A, Biamonti G, Montecucco A. Cell cycle-dependent phosphorylation of human DNA ligase I at the cyclin-dependent kinase sites. J Biol Chem 2003;278(39):37761-37767.
70. LoRusso PM, Canetta R, Wagner JA, Balogh EP, Nass SJ, Boerner SA, Hohneker J. Accelerating cancer therapy development: The importance of combination strategies and collaboration. Summary of an institute of medicine workshop. Clin Cancer Res 2012;18(22):6101-6109.